SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Yi, Seonju ; Choe, Young June ; Kim, Jia ; Kim, Yoo-Yeon ; Kim, Ryu Kyung ; Jang, Eun Jung ; Lim, Do Sang ; Byeon, Hye Ryeon ; Lee, Sangwon ; Park, Eonjoo ; Kim, Seung-Jin ; Park, Young-Joon
• Description:
  We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
• Subjects:
  Covid-19 Covid-19 Vaccines* Humans Retrospective Studies Sars-Cov-2
• Source:
  Emerg Infect Dis. 2022; 28(3):753-756
• Pubmed ID:
  35202529
• Pubmed Central ID:
  PMC8888240
• Document Type:
  Journal Article
• Genre:
  Letter
• Place as Subject:
  Republic of Korea
• Volume:
  28
• Issue:
  3
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:7da5a6d5efab49e9cae6e2ba9224dd19e02d3ff62475f07b9f99c6d6447c18c2
• Download URL:
  https://stacks.cdc.gov/view/cdc/115229/cdc_115229_DS1.pdf
• File Type:
  [PDF - 821.35 KB ]